Navigation Links
Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
Date:6/4/2008

SF1126 is a small-molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class I isoforms. In addition to inhibiting PI3 kinase, SF1126 inhibits mTOR, DNA-PK, Polo-like 1 kinases, PIM1 and CK2 - all believed to play significant roles in the control of cell survival/proliferation signals and in cancer. SF1126 is the only PI3K inhibitor demonstrated in preclinical studies to cause an oxidative stress mechanism in cancer cells, resulting in decreased proliferation and apoptosis. A major factor in tumor resistance to approved chemotherapy agents is thought to be the activation of the PI3K/PTEN pathway. As a result, it is believed that inhibiting this pathway with SF1126 could resensitize the cancer cells to approved anticancer agents and lead to possible synergistic anticancer activity. Clinical combination studies with SF1126 are being planned.

About Semafore Pharmaceuticals

Semafore Pharmaceuticals is a clinical-stage drug discovery and development company focused on small-molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus - cancer. Semafore is one of the first biopharmaceutical companies to focus on both PI3K and PTEN and has successfully discovered and is developing a portfolio of drug candidates addressing these targets.

Semafore is actively seeking partnerships or other strategic alliances to help fulfill the promise of SF1126. For more information visit the company's Web site at http://www.SemaforePharma.com .

Contacts:

Semafore Pharmaceuticals Inc.

Sandi Yurichuk

(650) 576-5769

sandi.yurichuk@semaforepharma.com

Russo Partners LLC

David Schull

(212) 845-4271

david.schull@russopartn
'/>"/>

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
2. Semafores SF1126 Exhibits Antitumor and Antiangiogenic Activity
3. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 21, 2014  Alere Inc. (NYSE: ... has appointed Juliet Cunningham as Vice President, ... be responsible for driving communications with the investment community. ... series of changes to increase shareholder value, it is ... said Namal Nawana, Chief Executive Officer. "We are delighted ...
(Date:11/21/2014)...  Tandem Diabetes Care ® , Inc. (NASDAQ: ... and manufacturer of the t:slim ® Insulin ... non-profit dedicated to improving diabetes therapy management by ... diabetes data accessibility. This partnership will enable users ... development, to download and access data from their ...
(Date:11/21/2014)... 21, 2014  World Hemp Oil, an importer of ... they are now offering legal, organic oil with high ... strains grown in medical marijuana states. People suffering from ... as Parkinson,s, MS, and spinal cord injury, no longer ... because imported CBD Oil Is legal in all states. ...
Breaking Medicine Technology:Alere Appoints Juliet Cunningham to Lead Investor Relations 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3
... VOLC ), a leading developer and manufacturer of ... and treatment of coronary and peripheral vascular disease, today announced ... quarter of fiscal 2011 on Wednesday, May 4. ... financial results and operating activities open to all interested parties ...
... Inc. (Nasdaq: PDII ) today announced that ... to enable eDetail delivery on popular mobile devices including ... iPhone ® (1) and Android™(2)-based phones. "With ... than the general population, we are moving quickly to ...
Cached Medicine Technology:Volcano Corporation Schedules First Quarter Conference Call, Webcast 2PDI Announces Group DCA's Launch of eDetailing Across Apple® and Android™ Mobile Devices 2
(Date:11/23/2014)... 23, 2014 The FDA is Watching: ... **FDAnews On-Demand Webinar**, Dec. 11, 2014 ? Any Time ... FDA’s focus on promotional activities is no longer limited ... they're looking at websites, Twitter, journal articles, TV appearances, ... Thursday, Dec. 11, for On-Demand access to Timothy Ayers ...
(Date:11/23/2014)... 2014 Wright & Schulte LLC recently ... and West Virginia residents who allege that they developed ... due to drinking C8 contaminated water released by ... According to the C8 complaints, the plaintiffs were exposed ... lived in at least one of the six water ...
(Date:11/23/2014)... 2014 Today Zane Benefits, the ... businesses, announced their new on demand webinar which ... Health Insurance. , According to Zane ... risk facing most American families. It is also ... large, when it comes to recruiting and retaining ...
(Date:11/22/2014)... A new AlignLife Chiropractic & Natural Health Center ... area. Dr. Chelsea Sineath, owner and chiropractor at ... own clinic after working in another AlignLife office and ... AlignLife believes that the body can heal itself when ... care and rehabilitation to allow the spine to maintain ...
(Date:11/22/2014)... 23, 2014 PrettyTailor , an ... a new big promotion. Customers can buy new dresses ... customers can visit its website. , As a matter ... occasion dresses. It mainly provides four types of wedding ... and flower girl dresses. It also provides a variety ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 3Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 4Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2
... EMERYVILLE, Calif., March 13 Bionovo, Inc.,(Nasdaq: ... quarter and,full year ended December 31, 2007., Fourth ... three months ended December 31,2007 of $330,875 compared to ... revenues over the comparable period in 2006, is due ...
... Tool Uniquely Provides Minute-by-Minute and Trend Information That Can ... Lead to ... The Food and Drug,Administration (FDA) has approved the ... the United,States for people with diabetes. Designed to discretely ...
... of convertible notes due June 2008 ... net operating expenses going forward Projects ... SEATTLE, March 13 Seattle-Cell Therapeutics,Inc. (CTI) (Nasdaq: CTIC ... quarter and twelve months ended December 31,2007., Recent Events, ...
... Inc., leaders in light therapy, proudly receives its ... ... Photo Therapeutics, Inc. is,pleased to announce it has received FDA approval ... of,periorbital wrinkles., (Photo: http://www.newscom.com/cgi-bin/prnh/20080312/LAW011 ), Omnilux New-U has ...
... FACEP (E), Executive,Director, American Public Health Association, ... (EPA) today announced more protective National Ambient,Air Quality ... recognize,the new standards as a much needed improvement ... Public Health Association (APHA) is concerned that,the allowed ...
... in poor neighborhoods most likely to watch TVs or computers, ... new survey reports that teenagers spend far too many hours ... in poor neighborhoods have even more "screen time." , "The ... some of these kids don,t have healthier alternatives in their ...
Cached Medicine News:Health News:Bionovo Announces 2007 Financial Results and Highlights 2Health News:Bionovo Announces 2007 Financial Results and Highlights 3Health News:Bionovo Announces 2007 Financial Results and Highlights 4Health News:Bionovo Announces 2007 Financial Results and Highlights 5Health News:Bionovo Announces 2007 Financial Results and Highlights 6Health News:Bionovo Announces 2007 Financial Results and Highlights 7Health News:Bionovo Announces 2007 Financial Results and Highlights 8Health News:FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System 2Health News:FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System 3Health News:FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System 4Health News:FDA Approves Abbott's FreeStyle Navigator(R) Continuous Glucose Monitoring System 5Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 2Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 3Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 4Health News:Omnilux New-U(TM) Hand-Held Device Receives FDA Approval 2Health News:APHA Says New Ozone Regulations a Missed Opportunity to Protect Public's Health 2Health News:Teens Spending Too Much Screen Time 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: